1. The Ademi Firm is investigating Cidara for fiduciary duty breaches. 2. Cidara's deal with Merck promises $221.50 per share, totaling $9.2 billion. 3. Concerns over a penalty limiting competing bids have arisen. 4. The nature of insider benefits in the deal draws scrutiny. 5. Shareholders may not be receiving a fair price.
Investigations of fiduciary breaches can lead to reduced investor confidence, harming stock value. The cautious approach usually leads to market skepticism and can depress stock prices as seen in similar cases.
The article discusses potential legal issues affecting shareholder value, impacting overall investor sentiment significantly.
Immediate concerns from the investigation can trigger short-term stock price declines. Historically, similar investigations have resulted in quick stock reactions within a few weeks to months.
MILWAUKEE, Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Cidara (NASDAQ:CDTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the tender offer transaction, Cidara shareholders will receive $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. Cidara insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Cidara by imposing a significant penalty if Cidara accepts a competing bid. We are investigating the conduct of the Cidara board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-cidara-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302615652.html
SOURCE Ademi LLP